Erratum: Formation of STAT5/PPARγ Transcriptional Complex Modulates Angiogenic Cell Bioavailability in Diabetes (Arteriosclerosis, Thrombosis, and Vascular Biology (2009) 29 (114-120) DOI: 10.1161/ATVBAHA.108.172247);Formation of STAT5/PPARγ transcriptional complex modulates angiogenic cell bioavailability in diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 1, 2009, Pages 114-120

  Dentelli, Patrizia ^a   Trombetta, Antonella ^a   Togliatto, Gabriele ^a   Zeoli, Annarita ^a   Rosso, Arturo ^a   Uberti, Barbara ^a   Orso, Francesca ^b   Taverna, Daniela ^b   Pegoraro, Luigi ^a   Brizzi, Maria Felice ^a,c  

^a Molecular Biotechnology Center   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenesis; Diabetes; EPC; PPAR ; ST

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLIN D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SMALL INTERFERING RNA; STAT5 PROTEIN; LUCIFERASE; MESSENGER RNA; RNA;

ADULT; ANGIOGENESIS; ARTICLE; BIOAVAILABILITY; CELL; CELL CYCLE PROGRESSION; CHROMATIN IMMUNOPRECIPITATION; CIRCULATING ANGIOGENIC CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DNA RESPONSIVE ELEMENT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SITE DIRECTED MUTAGENESIS; ANIMAL; BLOOD; BONE MARROW CELL; DIABETIC ANGIOPATHY; GENETICS; ISOLATION AND PURIFICATION; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW CELLS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RNA; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 58849163113     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATV.0000000000000155     Document Type: Erratum

References (38)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet (United States). Atlanta, Ga: Centers for Disease Control and Prevention; 2005.
2. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10:355-361.
3. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-424.
4. Krey G, Keller H, Mahfoudi A, Medin J, Ozato K, Dreyer C, Wahli W. Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J Steroid Biochem Mol Biol. 1993;47:65-73.
5. IJpenberg A, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem. 1997;272:20108-20117.
6. Auwerx J, Martin G, Guerre-Millo M, Staels B. Transcription, adipocyte differentiation, and obesity. J Mol Med. 1996;74:347-352.
7. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med. 2000;38:3-11.
8. Komers R, Vrana A. Thiazolidinediones: tools for the research of metabolic syndrome X. Physiol Res. 1998;47:215-225.
9. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol. 2001;12:511-518.
10. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497-505.
11. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006;6:421-427.
12. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008; 102: 283-294.
13. Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ: Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J. 2006;152:el-e8.
14. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
15. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007;21:1141-1149.
16. Zeoli A, Dentelli P, Rosso A, Togliatto G, Trombetta A, Damiano L, Francia di Celle P, Pegoraro L, Altruda F, Brizzi MF. Interleukin-3 (IL-3) promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation. Blood. 2008;112:350-361.
17. Brizzi MF, Dentelli P, Gambino R, Cabodi S, Cassader M, Castelli A, Defilippi P, Pegoraro L, Pagano G. STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity. Diabetes. 2002;51:3311-3317.
18. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 1997;15:105-111.
19. Stephens JM, Morrison RF, Wu Z, Farmer SR. PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis. Biochem Biophys Res Commun. 1999;262:216-222.
20. Shipley JM, Waxman DJ. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol. 2003;64:355-364.
21. Olsen H, Haldosén LA. Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A. Exp Cell Res. 2006;312:1371-1380.
22. Dai X, Sayama K, Shirakata Y, Hanakawa Y, Yamasaki K, Tokumaru S, Yang L, Wang X, Hirakawa S, Tohyama M, Yamauchi T, Takashi K, Kagechika H, Hashimoto K. STAT5a/PPARgamma pathway regulates involucrin expression in keratinocyte differentiation. J Invest Dermatol. 2007;127:1728-1735.
23. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
24. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, Miyajima A, Kitamura T. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871-3879.
25. Defilippi P, Rosso A, Dentelli P, Calvi C, Garbarino G, Tarone G, Pegoraro L, Brizzi MF. (beta) 1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. J Cell Biol. 2005;168:1099-1108.
26. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993;261:1739-1744.
27. Buitenhuis M, Coffer PJ, Koenderman L. Signal transducer and activator of transcription 5 (STAT5). Int J Biochem CellBiol. 2004;36:2120-2124.
28. Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P. A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol. 2003;23:289-294.
29. Prost S, Le Dantec M, Augé S, Le Grand R, Derdouch S, Auregan G, Déglon N, Relouzat F, Aubertin AM, Maillere B, Dusanter-Fourt I, Kirszenbaum M. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/STAT5 signaling pathway in macaques. J Clin Invest. 2008;118:1765-1775.
30. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007;30:1305-1313.
31. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244-251.
32. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene. 2006;25:6868-6886.
33. Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007;82:275-281.
34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
35. Fadini GP, Agostini C, Avogaro A. Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectives. Curr Diabetes Rev. 2005;1:41-58.
36. Rosso A, Balsamo A, Gambino R, Dentelli P, Falcioni R, Cassader M, Pegoraro L, Pagano G, Brizzi MF. p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem. 2006;281:4339-4347.
37. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group: Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007;357:28-38.
38. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA. 2007;298:1180-1188.